®

Lynx Biosciences™, Inc. (LynxBio ) is a clinical-stage biotechnology company combining physiologically relevant suspension cell co-culture assays, automated microfluidics, and deep learning analytics with the goal of rapidly advancing drug candidates in oncology and bringing personalized cancer treatments to patients.

 
CellCapture_02.PNG

Deep phenotypic profiling and functional characterization of suspension cells can be technically challenging due to their susceptibility to physical perturbations. We are harnessing the power of our multi-omic platform to characterize complex diseases and treatments where suspension cells play critical roles, including hematological cancers, immunotherapies, and cell-based therapies.

 
Lynx Bio Partnering Photo 2.jpg

As a (re)mission-driven company, we leverage this clinically-proven platform to address unmet medical needs in oncology, with an initial focus on hematological malignancies. To date, we have entered into collaborations with underserved community hospitals, 12+ NCI-designated cancer centers, as well as top 10 pharmaceutical companies to advance promising drug candidates and identify predictive biomarkers in clinical studies.

 

3210 Merryfield Row

San Diego, CA 92121-1126

  • White LinkedIn Icon
  • White Twitter Icon
  • Email icon-02

All content copyright © 2020 Lynx Biosciences™, Inc. All rights reserved. LynxBio   is a registered trademark of Lynx Biosciences™, Inc.

®